icon-folder.gif   Conference Reports for NATAP  
 
  64rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Washington, DC Nov 1-5 2013
Back grey_arrow_rt.gif
 
 
 
BMS at AASLD
 
 
  AASLD: Phase 2b Study of the Interferon-Free and Ribavirin-Free Combination of Daclatasvir, Asunaprevir, and BMS-791325 for 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 1 Infection - (11/05/13)
 
Phase 3 Study:
http://www.clinicaltrials.gov/ct2/show/NCT01973049?term=bms-791325&rank=2v As well PegLambda is in phase 3 studies now.
 
AASLD: All-Oral Combination of Daclatasvir Plus Asunaprevir in Interferon-Ineligible Na´ve/Intolerant and Nonresponder Japanese Patients Chronically Infected With HCV Genotype 1b: Results From a Phase 3 Trial - (11/06/13)
 
AASLD: Safety and Efficacy of BMS-791325, a Non-Nucleoside NS5B Polymerase Inhibitor, Combined With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients Infected with Hepatitis C Virus Genotype 1 - (11/13/13)
 
AASLD: Lack of Pharmacokinetic Interaction Between HCV Protease Inhibitor MK-5172 and HCV NS5A Inhibitor Daclatasvir in Healthy Volunteers - (11/13/13)
 
AASLD: BMS Submits First All-Oral, Interferon-Free and Ribavirin-Free Treatment Regimen for Regulatory Review in Japan for Patients with Chronic Hepatitis C Infection - (11/02/13)
 
64rd Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC Nov 1-5 2013